NO20016067L - Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister - Google Patents

Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister

Info

Publication number
NO20016067L
NO20016067L NO20016067A NO20016067A NO20016067L NO 20016067 L NO20016067 L NO 20016067L NO 20016067 A NO20016067 A NO 20016067A NO 20016067 A NO20016067 A NO 20016067A NO 20016067 L NO20016067 L NO 20016067L
Authority
NO
Norway
Prior art keywords
preparation
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO20016067A
Other languages
English (en)
Other versions
NO20016067D0 (no
NO314301B1 (no
Inventor
Deborah Lynn Bryan
John Gerald Gleason
Katherine Louisa Widdowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20016067L publication Critical patent/NO20016067L/no
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20016067D0 publication Critical patent/NO20016067D0/no
Publication of NO314301B1 publication Critical patent/NO314301B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20016067A 1996-08-15 2001-12-12 Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister NO314301B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2341496P 1996-08-15 1996-08-15
PCT/US1997/014581 WO1998006397A1 (en) 1996-08-15 1997-08-15 Il-8 receptor antagonists

Publications (3)

Publication Number Publication Date
NO20016067L true NO20016067L (no) 1999-04-12
NO20016067D0 NO20016067D0 (no) 2001-12-12
NO314301B1 NO314301B1 (no) 2003-03-03

Family

ID=21814968

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19990668A NO312458B1 (no) 1996-08-15 1999-02-12 IL-8-reseptor antagonister, fremgangsmåte for fremstilling derav og farmasöytisk preparat
NO20016067A NO314301B1 (no) 1996-08-15 2001-12-12 Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19990668A NO312458B1 (no) 1996-08-15 1999-02-12 IL-8-reseptor antagonister, fremgangsmåte for fremstilling derav og farmasöytisk preparat

Country Status (18)

Country Link
US (1) US6204294B1 (no)
EP (1) EP0929302A4 (no)
JP (1) JP2000516619A (no)
KR (1) KR20000030003A (no)
CN (1) CN1152675C (no)
AR (1) AR008290A1 (no)
AU (1) AU723816B2 (no)
BR (1) BR9711140A (no)
CA (1) CA2263388A1 (no)
CO (1) CO5031286A1 (no)
CZ (1) CZ46799A3 (no)
IL (1) IL128501A0 (no)
NO (2) NO312458B1 (no)
PL (1) PL331539A1 (no)
TR (1) TR199900318T2 (no)
TW (1) TW461878B (no)
WO (1) WO1998006397A1 (no)
ZA (1) ZA977301B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4073489B2 (ja) 1996-05-24 2008-04-09 ニューロサーチ・アクティーゼルスカブ 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法
EP0932405A4 (en) 1996-06-27 2001-10-17 Smithkline Beckman Corp IL-8 RECEPTOR ANTAGONISTS
JP2000516621A (ja) * 1996-08-15 2000-12-12 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
AR029637A1 (es) * 1999-05-28 2003-07-10 Smithkline Beecham Corp Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
CO5170528A1 (es) * 1999-05-28 2002-06-27 Smithkline Beecham Corp Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8
ECSP003525A (es) * 1999-06-16 2002-01-25 Smithkline Beecham Corp Antagonistas del receptor de il- 8 iv
UY26627A1 (es) 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
AU2001248753B2 (en) 2000-04-14 2004-12-23 Kureha Corporation Nitrogenous compounds and antiviral drugs containing the same
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
EP1389460A1 (en) * 2001-05-24 2004-02-18 Kureha Chemical Industry Co., Ltd. Cxcr4-antagonistic drugs comprising nitrogen-containing compound
JP3714948B2 (ja) * 2002-09-11 2005-11-09 呉羽化学工業株式会社 アミン化合物及びその用途
AR041834A1 (es) * 2002-10-29 2005-06-01 Smithkline Beecham Corp Compuesto de difenilurea sustituido con sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
JP3977411B2 (ja) * 2004-03-10 2007-09-19 株式会社クレハ アミン系塩基性化合物とその用途
MXPA06013118A (es) 2004-05-12 2007-02-28 Schering Corp Antagonistas de cxcr1 y cxcr2 de quimocina.
WO2006023435A1 (en) * 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
EP1634573A1 (en) * 2004-08-16 2006-03-15 The Procter and Gamble Company 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
EP1812008A4 (en) * 2004-10-20 2008-10-29 Smithkline Beecham Corp ANTAGONISTS OF THE IL-8 RECEPTOR
AU2007240364A1 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation IL-8 receptor antagonists
PL2009992T3 (pl) * 2006-04-21 2012-11-30 Glaxosmithkline Llc Antagoniści receptora IL-8
PE20080943A1 (es) * 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537186A (en) * 1895-04-09 Jacob ebert
US4269837A (en) * 1980-02-19 1981-05-26 Pfizer Inc. Hypoglycemic guanylamidines, compositions and use
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
US5214208A (en) * 1989-03-13 1993-05-25 Canon Kabushiki Kaisha Toner containing a dimer of diarylguanidine type compound for developing electrostatic image
JP2742084B2 (ja) * 1989-03-13 1998-04-22 キヤノン株式会社 グアニジン二量化物およびグアニジン二量化物を含有する静電荷像現像用トナー
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5371086A (en) * 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
AU4530693A (en) * 1992-08-13 1994-03-15 Upjohn Company, The Cyanoguanidines as potassium channel blockers
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds

Also Published As

Publication number Publication date
CO5031286A1 (es) 2001-04-27
NO990668L (no) 1999-04-12
EP0929302A1 (en) 1999-07-21
NO20016067D0 (no) 2001-12-12
US6204294B1 (en) 2001-03-20
TW461878B (en) 2001-11-01
JP2000516619A (ja) 2000-12-12
AR008290A1 (es) 1999-12-29
CA2263388A1 (en) 1998-02-19
PL331539A1 (en) 1999-07-19
TR199900318T2 (xx) 1999-05-21
CN1232398A (zh) 1999-10-20
NO314301B1 (no) 2003-03-03
CZ46799A3 (cs) 1999-12-15
EP0929302A4 (en) 2002-10-31
CN1152675C (zh) 2004-06-09
NO312458B1 (no) 2002-05-13
NO990668D0 (no) 1999-02-12
ZA977301B (en) 1998-02-16
AU4075097A (en) 1998-03-06
IL128501A0 (en) 2000-01-31
WO1998006397A1 (en) 1998-02-19
BR9711140A (pt) 1999-08-17
KR20000030003A (ko) 2000-05-25
AU723816B2 (en) 2000-09-07

Similar Documents

Publication Publication Date Title
NO20016067L (no) Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister
NO983737L (no) IL-8 reseptor antagonister
PL339134A1 (en) Antagonists of il-8 receptor
PL334756A1 (en) Antagonists of il-8 receptor
BR9709952A (pt) Antagonistas de receptor de il-8
PL330849A1 (en) Antagonists of il-8 receptors
MA24361A1 (fr) Procede pouyr la preparation d'antagonistes de recepteur de vitronectine
NO972016D0 (no) Indolyl-Y-reseptorantagonister
BR9609687A (pt) Preparado de cimento
BR9612327A (pt) Antagonistas receptores de vitronectina
ID16742A (id) Antagonis reseptor endotelin
PT1036072E (pt) Antagonistas de receptores de trombina
PL334774A1 (en) Antagonists of il-8 receptor
PL335100A1 (en) Oxazolynones as antagonists of 5ht2a receptor
PL339133A1 (en) Antagonists of il-8 receptor
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO993065L (no) Fremgangsmåte for fremstilling av NMDA-antagonister
NO20004422D0 (no) FremgangsmÕte for fremstilling av sulfanyl-type endothelinreseptor-antagonister
NO955296D0 (no) Fremgangsmåte for fremstilling av betongkonstruksjon
IL141121A0 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees